New Agents for GI Malignancies
Bereit, Ihre Wellness-Reise zu starten
Disclosures: Robert Wong: Theratechnologies: Grant/Research Support, Durect: Grant/Research Support, Gilead Sciences: Grant/Research Support, Exact Sciences: Grant/Research Support, Theratechnologies: Grant/Research Support, Durect Corporation: Grant/Research Support, Leland Yee: Gilead Sciences: Employee, Yunhao Liu: Gilead Sciences: Employee, Laura Telep: Gilead Sciences, LLC: Employee, Gilead Sciences, LLC: Stock - publicly traded company, Shahed Iqbal: Gilead Sciences, Inc.: Stockholder, Gilead Sciences, Inc.: Stock - publicly traded company, Gilead Sciences, Inc.: Employee, Sarjita Naik: Gilead Sciences: Employee, Gilead Sciences: Stock privately held company, Betty Chiang: Nothing to Disclose, Amanda Singer: Gilead Sciences: Employee, Gilead Sciences: Stock - publicly traded company, Anand Chokkalingam: Nothing to Disclose, Catherine Frenette: Nothing to Disclose 907 DISPARITIES IN PRIMARY BILIARY CHOLANGITIS: A RETROSPECTIVE STUDY USING REAL-WORLD DATA FROM A SINGLE HEPATOLOGY CLINIC IN THE GREATER LOS ANGELES AREA Sabrina Alff 1 Orlinda Ventura 1 Trinity Love Foster-Malave 1 Michel Mendler 1 Edward Mena 2 , 1 California Liver Research Institute, 2 California Liver Reasearch Institiute Background: Primary Biliary Cholangitis (PBC) is an autoimmune disease that leads to cirrhosis
EXTRAIT DE : MYRTILLE, GRENADE, PIN SYLVESTRE
Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice
